《大行報告》高盛下調京東健康(06618.HK)目標價至75元評級「買入」 | uSMART

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

uSMART

EN

《大行報告》高盛下調京東健康(06618.HK)目標價至75元評級「買入」

阿思達克 10-24 10:26

高盛發表報告，預計醫療保健科技行業按年增長將相對疲軟，B2C/B2B行業趨勢分化。予京東健康(06618.HK)「買入」評級，目標價降至75元。對於B2C平台京東健康和阿里健康(00241.HK)，該行認為第三季按年增長率仍為正數，且上季度的月度增長率亦在不斷提高。而B2B行業的增長低谷期可能已經過去，大數據/IT領域的醫院招標仍需要更多時間恢復。

京東健康(06618.HK)

京東健康-R(86618.HK)

阿里健康(00241.HK)

Relevant Stocks

京東健康(06618.HK)

京東健康-R(86618.HK)

阿里健康(00241.HK)

Contact Us

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSMART-Facebook-Page

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Copyright © 2022 uSMART . All Rights Reserved.